• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    12/12/23 8:07:33 AM ET
    $ACHV
    $AEON
    $CADL
    $CCCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACHV alert in real time by email

    Gainers

    • C4 Therapeutics (NASDAQ:CCCC) stock rose 59.7% to $1.89 during Tuesday's pre-market session. The company's market cap stands at $92.8 million.
    • Candel Therapeutics (NASDAQ:CADL) stock increased by 47.38% to $1.28. The company's market cap stands at $37.0 million.
    • Icosavax (NASDAQ:ICVX) shares increased by 45.85% to $15.3. The market value of their outstanding shares is at $766.3 million.
    • AEON Biopharma (AMEX:AEON) stock moved upwards by 33.07% to $8.65. The market value of their outstanding shares is at $321.4 million.
    • IN8bio (NASDAQ:INAB) stock rose 28.12% to $1.64. The company's market cap stands at $52.4 million.
    • Sonoma Pharmaceuticals (NASDAQ:SNOA) stock rose 23.06% to $0.21. The market value of their outstanding shares is at $2.8 million.

    Losers

    • CareCloud (NASDAQ:CCLDP) shares declined by 35.9% to $9.77 during Tuesday's pre-market session.
    • Achieve Life Sciences (NASDAQ:ACHV) stock decreased by 26.61% to $4.0. The market value of their outstanding shares is at $84.6 million.
    • Assure Hldgs (NASDAQ:IONM) shares fell 24.4% to $0.33. The company's market cap stands at $2.1 million.
    • Pasithea Therapeutics (NASDAQ:KTTA) stock declined by 15.68% to $0.37. The market value of their outstanding shares is at $7.7 million.
    • CareCloud (NASDAQ:CCLDO) stock decreased by 15.02% to $11.74.
    • Nexalin Technology (NASDAQ:NXL) stock decreased by 11.98% to $0.46. The market value of their outstanding shares is at $3.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACHV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHV
    $AEON
    $CADL
    $CCCC

    CompanyDatePrice TargetRatingAnalyst
    C4 Therapeutics Inc.
    $CCCC
    12/2/2025Buy
    TD Cowen
    Achieve Life Sciences Inc.
    $ACHV
    11/25/2025$19.00Mkt Outperform
    Citizens JMP
    Candel Therapeutics Inc.
    $CADL
    10/28/2025$15.00Overweight
    Stephens
    C4 Therapeutics Inc.
    $CCCC
    9/17/2025$8.00Overweight
    Barclays
    C4 Therapeutics Inc.
    $CCCC
    9/15/2025$6.00Equal-Weight → Overweight
    Stephens
    C4 Therapeutics Inc.
    $CCCC
    9/4/2025$8.00Buy
    Guggenheim
    Candel Therapeutics Inc.
    $CADL
    9/3/2025$7.00Buy → Neutral
    BofA Securities
    Achieve Life Sciences Inc.
    $ACHV
    8/21/2025$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACHV
    $AEON
    $CADL
    $CCCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on C4 Therapeutics

    TD Cowen initiated coverage of C4 Therapeutics with a rating of Buy

    12/2/25 8:23:26 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citizens JMP initiated coverage on Achieve Life Sciences with a new price target

    Citizens JMP initiated coverage of Achieve Life Sciences with a rating of Mkt Outperform and set a new price target of $19.00

    11/25/25 8:38:19 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Stephens initiated coverage on Candel Therapeutics with a new price target

    Stephens initiated coverage of Candel Therapeutics with a rating of Overweight and set a new price target of $15.00

    10/28/25 8:02:46 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHV
    $AEON
    $CADL
    $CCCC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manning Paul B bought $2,999,996 worth of shares (550,458 units at $5.45) (SEC Form 4)

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    2/26/26 7:38:59 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Steinman Lawrence bought $100,000 worth of shares (133,333 units at $0.75), increasing direct ownership by 201% to 199,691 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 9:07:14 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Marques Tiago bought $25,000 worth of shares (33,333 units at $0.75), increasing direct ownership by 83% to 73,334 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 8:56:56 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACHV
    $AEON
    $CADL
    $CCCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AEON Biopharma Appoints John Bencich as Chief Financial Officer

    IRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced the appointment of John Bencich as Chief Financial Officer. Mr. Bencich joins AEON at a pivotal stage in the Company's evolution as it prepares to execute through its next phase of critical regulatory milestones. "John's appointment represents an important step forward for AEON as we enter a period of accelerated execution," said Rob Bancroft, President and Chief Executive Officer of AEON. "His d

    3/9/26 4:05:00 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    WATERTOWN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company's common stock to one new employee (the "Inducement Grant"), with the grant made on March 9, 2026 (the "Grant Date"). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Li

    3/9/26 4:01:00 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

    NEEDHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for oral presentation in the Practice-changing, Paradigm-shifting Clinical Trials in Urology session, as part of the American Urological Association (AUA) 2026 Annual Meeting Plenary Program being held in Washington D.C. from May 15-18, 2026. The presentation will feature new data from the Company's phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with interm

    3/9/26 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHV
    $AEON
    $CADL
    $CCCC
    SEC Filings

    View All

    AEON Biopharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AEON Biopharma, Inc. (0001837607) (Filer)

    3/9/26 4:05:20 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by IN8bio Inc.

    SCHEDULE 13G - IN8BIO, INC. (0001740279) (Subject)

    3/2/26 2:01:20 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by IN8bio Inc.

    8-K - IN8BIO, INC. (0001740279) (Filer)

    2/27/26 4:05:35 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHV
    $AEON
    $CADL
    $CCCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CLO, CSO, and Corp Secretary Wilson Alexander Blair was granted 2,179,372 shares, increasing direct ownership by 59,988% to 2,183,005 units (SEC Form 4)

    4 - AEON Biopharma, Inc. (0001837607) (Issuer)

    3/5/26 6:07:56 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRINCIPAL ACCOUNTING OFFICER Sy Jennifer was granted 1,500,925 shares, increasing direct ownership by 597,978% to 1,501,176 units (SEC Form 4)

    4 - AEON Biopharma, Inc. (0001837607) (Issuer)

    3/5/26 6:06:25 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Manning Paul B bought $2,999,996 worth of shares (550,458 units at $5.45) (SEC Form 4)

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    2/26/26 7:38:59 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHV
    $AEON
    $CADL
    $CCCC
    Leadership Updates

    Live Leadership Updates

    View All

    AEON Biopharma Appoints John Bencich as Chief Financial Officer

    IRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced the appointment of John Bencich as Chief Financial Officer. Mr. Bencich joins AEON at a pivotal stage in the Company's evolution as it prepares to execute through its next phase of critical regulatory milestones. "John's appointment represents an important step forward for AEON as we enter a period of accelerated execution," said Rob Bancroft, President and Chief Executive Officer of AEON. "His d

    3/9/26 4:05:00 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

    HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. ("Carmi Masha"), a leading Israeli medical device distributor, to market and sell Nexalin's Gen-2 Console ("SYNC"), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel. This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin's Gen-2 SYNC device in Israel for the treatment of a var

    11/13/25 9:15:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

    SEATTLE and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) --  Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced the appointment of Erik Atkisson as Chief Legal Officer. In his new role, Mr. Atkisson will oversee Achieve's legal strategy, corporate governance, compliance, and risk management. "Erik's extensive legal, regulatory and M&A background in the biopharmaceutical sector provides valuable experience as we advance cytisinicline through regulatory review and prepare for a potential laun

    10/20/25 8:30:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    $AEON
    $CADL
    $CCCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by C4 Therapeutics Inc.

    SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 7:53:04 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by C4 Therapeutics Inc.

    SC 13G - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 6:43:36 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHV
    $AEON
    $CADL
    $CCCC
    Financials

    Live finance-specific insights

    View All

    AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

    – FDA Type 2a meeting scheduled for November 19, 2025, to review AEON's analytical development plan and initial data – – Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing and highly similar functional characteristics submitted to FDA ahead of scheduled Type 2a meeting – – Two complementary financing transactions announced in November 2025 - $6 million PIPE financing and a proposed Daewoong note exchange - are expected to strengthen AEON's balance sheet, reduce outstanding debt by more than 90%, accelerate the ABP-450 biosimilar program by up to six months, and extend cash runway into the second quarter of 2026 – IRVINE, Calif., Nov. 14, 2025 (GLOBE

    11/14/25 8:30:00 AM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025

    SEATTLE and VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its third quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Thursday, November 6, 2025, at 8:30 AM EST. To access the webcast, please use the following link: 3Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 888-396-8049 (U.S. & Canada) or 416-764-8646 (International) and

    10/29/25 8:30:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    – Multiple near-term potential milestones, including anticipated completion of primary structure analysis and select functional analyses in 3Q'25 – – Type 2a meeting with the FDA anticipated in 4Q'25– – Cash runway expected to support operations through FDA meeting and regulatory feedback – IRVINE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company seeking an accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX® (onabotulinumtoxinA) biosimilar, announced its financial results for the second quarter ended June 30, 2025, and provided a business update. "We have ma

    8/12/25 4:05:00 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care